NKF advised GENFIT on its acquisition of Versantis 

Niederer Kraft Frey has advised GENFIT, a late-stage biopharmaceutical company, on the acquisition of Versantis. GENFIT is a pioneer in liver disease research and development, publicly traded company listed on the Nasdaq Global Select Market and on compartment B of Euronext’s regulated market in Paris. The acquisted Versantis is a clinical stage biotechnology company focused on addressing the growing, unmet medical need in liver diseases.

This partnership enables the combination of Versantis’ experience with GENFIT’s expertise in conducting complex development programmes in liver diseases. The acquisition further strengthens GENFIT’s position as a leader in acute-chronic liver failure (ACLF) and significantly expands its product portfolio.

The NKF team was led by corporate/m&a partner Philipp Haas (pictured left) and tax partner Daniela Schmucki (pictured right), working with senior associates Shu Bernet-Zhang and Julia Tolstova (both corporate/m&a) as well as partners Ulysses von Salis (corporate/m&a), Christina Rinne (tax) and Andreas Casutt (employment), senior associate Morgan Boëffard (tax), associate Daniela Lötscher (employment) and associate Jamie Lee Mancini (real estate).